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Introduction
Dopamine (DA) is well know to effect directly the
anterior pituitary gland. It has been known for many
decades that DA plays a role as the main hypothalam-
ic inhibiting factor of prolactin secretion [1,2]. In
1978 Pawlikowski et al. [3] showed that DA directly
inhibits the pituitary growth The dopamine receptors,
which are responsible for the direct effects of DA at
the anterior pituitary level, were characterized as
belonging to D2 type [for review see 4]. A synthesis
of bromocriptine, a first selective and long-lasting
agonist of D2 receptors, allowed to introduce this
drug to the medical treatment of pituitary adenomas,
particularly prolactinomas [5]. Nowadays bromocrip-
tine and other newer D2 agonists consist a first line
treatment for prolactinomas [6]. Dopamine agonists
were also applied in the treatment of acromegaly,
because of the paradoxical action of DA on growth
hormone secretion in acromegalic patients [7]. How-
ever, their effects are poorer in comparison to the long-
acting somatostatin analogs like octreotide and lan-
reotide. Clinical trials suggest that DA receptors ago-
nists are also effective in the treatment of the non-
functioning pituitary adenomas [for review see 8].
Recently, the chimeric molecules acting simultaneous-
ly on somatostatin 2A and dopamine D2 receptors
were developed and their enhanced potency in inhibit-
ing both growth hormone and prolactin secretion was
shown [9]. These compounds were also found to sup-
press in vitro the viability of cells isolated from the
clinically nonfunctioning pituitary adenomas and were
suggested as potential future medical treatment for this
type of malignancies [8,10].
Material and methods
Tissue samples. Thirty one human pituitary adenomas, surgically
excised, were examined. The material included 7 samples of
acromegaly, 7 prolactinomas, 8 clinically nonfunctioning adeno-
mas expressing gonadotropins, 4 clinically nonfunctioning pluri-
hormonal adenomas and 5 corticotropinomas (4 manifesting as
Cushing's disease and 1 silent corticotropinoma). In the group of
plurihormonal adenomas, 2 expressed GH, PRL and LH, 1 GH,
FSH and LH, and the remaining 1 GH and LH. Additionally, three
samples of the non-tumoral anterior pituitary gland, adjacent to the
excised tumors were also examined. 
Immunohistochemistry. D2 receptor immunostaining was per-
formed using the rabbit anti-human dopamine receptor D2 poly-
clonal antibody .This antibody was raised against the 28 amino
acid sequence from the human D2 receptor within the cytoplasmic
loop 3 and recognizes both long and short form of the human
receptor, and its specifity was approved in earlier publications
[11,12] The antibody was purchased from Chemicon International
(USA Canada). It was applied in working dilution 1:100.
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Each human tumor was also immunostained using the primary
polyclonal or monoclonal antibodies against the pituitary hor-
mones and alpha-subunit (alpha-SU).The following primary anti-
bodies against the pituitary hormones were used: anti-prolactin
(polyclonal, Dako, Denmark). Anti-growth hormone (polyclonal,
Dako), anti-LH (monoclonal, Dako), anti-FSH (monoclonal,
Dako) anti-TSH (monoclonal, Immunotech, France) anti-ACTH
(polyclonal, Sigma) and anti- alpha-SU (monoclonal, Immunotech,
France). The more detailed informations on pituitary hormone
immunohistochemistry were published in an earlier paper [13].
The hormone immunohistochemistry, taken together with clinical
data, served to classification of pituitary adenoma samples (see
above). The visualization of primary anti-receptor and anti-hor-
mone antibodies was done using the StreptABComplex/HRP Duet
(Dako Cytomation) following the procedure recommended by the
manufacturer.. In brief, the biotinylated goat antibody against rab-
bit and mouse immunoglobulin was applied as the secondary anti-
body, followed by streptavidin-biotinylated horseradish peroxidase
complex and 3,3'-diaminobenzidine as chromogen.
Ethical issues. The study was approved by the Local Bioethical
Committee, decision number RNN/191/09/ KE dated September,
22th 2009.
Results
In non-tumoral anterior pituitary tissues as well as in
pituitary adenomas, the positive immunostaining with
anti-D2 receptor antibody in the investigated tissues
appears in two main localizations. The weak to mod-
erate cytoplasmic immunostaining concerns majority,
or in other cases, only some groups of cells (Fig. 1 and
2). Only in 3 cases of pituitary adenomas the
immunostaining of cell membranes was also found
(Fig. 3). It concerned 2 samples of prolactinomas and
1 sample of somatotropinoma in acromegalic patient.
The moderate to strong immunostaining was also
observed in a subpopulation of cell nuclei (Fig. 4) and
in the walls of blood vessels (Fig. 5). In the normal
peritumoral anterior pituitary tissues, the D2 receptor
immunostaining of cell cytoplasm was found in two
samples. The immunostaining was weak to moderate
and concerned almost all glandular cells. In one sam-
ple the cytoplasmic immunoreaction was absent, but
nuclear immunostaining was visible in a small sub-
population of nuclei (<10%). Moreover, in one sample
we could see the D2 immunopositivity in blood vessel
walls. In pituitary adenomas, cytoplasmic and/or
nuclear D2 immunostaining was detectable in 22 but
absent in 8 tumors. The expression seems to be high-
est in prolactinomas (7/7). In acromegaly the positive
D2 staining occurred in 5/7 samples, in
gonadotropinomas in 6/8 and in plurihormonal adeno-
mas in 2/4. The lowest expression was observed in cor-
ticotropinomas (1/5). If we consider only cytoplasmic
localization of D2 immunostaining, the following fre-
quences were observed: prolactinomas 6/7, soma-
totropinomas 4/7, gonadotropinomas 3/8, corti-
cotropinomas 1/5 and plurihormonal adenomas 1/4.
The D2- immunopositive intratumoral blood vessels
were found in 18 specimens. In three cases, D2-
immunopositive blood vessels occurred in spite of the
absence of immunoreaction in glandular cells. In
respect to the hormonal phenotype of the adenomas,
the vascular D2 immunopositivity occurs mostly in
gonadotropinomas (6/8) but is rare in corticotropino-
mas (1/5) and plurihormonal adenomas (1/4).
Discussion
The data presented above confirm the earlier studies
showing that dopamine D2 receptors are detectable in
pituitary adenoma cells by immunohistochemistry [14-
16]. The highest expression of D2 immunopositivity in
prolactinomas corroborates with the well known effi-
cacy of dopamine agonists in the treatment of this kind
of pituitary tumors. The relatively high expression of
D2 receptors in GH-secreting adenomas in patients
suffering from acromegaly is in agreement with the
data reported by Ferone et al. [14] and Stefaneanu et
al.[16] and are compatible with the partial responsive-
ness of these tumors to dopamine agonists. The high
incidence of D2 immunopositivity was found in clini-
cally nonfunctioning pituitary adenomas diagnosed
immunohistochemically as gonadotropinomas (75%).
This result is roughly similar to that reported by
Pivonello et al. [17], who have found the expression of
D2 receptor mRNA, by means of RT-PCR technique,
in approximatively 70% of clinically nonfunctioning
pituitary adenomas. The quoted authors showed also
that cabergoline treatment of the patients resulted in
56% of cases in significant tumor shrinkage, and the
effect correlated with the D2 receptor expression,
especially that of short isoform. In our  earlier study
we showed that exposure of cells isolated from clini-
cally nonfunctioning pituitary adenomas (mostly
gonadotropinomas) cultured in vitro to bromocriptine
or to dopamine-somatostatin chimeric molecule BIM
23A387 resulted in 60% of samples by  reduced cell
viability [10]. In our material, the expression of D2
receptors in corticotropinomas was rather low (20%).
It seems to stay in opposition to the observations of
Pivonello et al. [15] and Stefaneanu et al. [16] who
found D2 receptors expressed in 80% and 70% of the
investigated corticotroph adenomas, respectively.
However, our material of corticotropinomas was small
and our estimation of frequency is not conclusive.
Besides from the cytoplasmic localization, which was
reported also by other authors applying the immuno-
histochemical method to detect the D2 receptors in
pituitary tumors [14,16], we observed also a nuclear
immunostaining. This nuclear staining usually was
accompanied by cytoplasmic immunopositivity, but
sometimes appeared in spite of the immunonegative
cytoplasm. The meaning of such nuclear localization,
noticed earlier also by Stefaneanu et al. [16], remains
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to be recognized in further studies. Another unexpect-
ed localization of D2 immunopositivity concerns the
blood vessel walls. This localization seems to corrob-
orate with the recent data demonstrating the role of
dopamine and D2 receptors in angiogenesis.
Dopamine acting via D2 receptors was shown to sup-
press the action of vascular endothelial growth factor
A on both tumor endothelial and bone-marrow derived
396 M. Pawlikowski
©Polish Histochemical et Cytochemical Society
Folia Histochem Cytobiol. 2010:48(3): 396 (394-397) 
10.2478/v10042-010-0031-1
Fig. 1. Moderate cytoplasmic immunostaining with anti-D2 receptor antibody in the prolactinoma (man, 45 years old, original magnifi-
cation ×400). Fig. 2. A cluster of D2-immunopositive cells of prolactinoma (woman, 59 years old, original magnification ×400). 
Fig. 3. Membrane localization of D2 receptor immunostaining in prolactinoma (man, 58 years old, original magnification ×400). 
Fig. 4. D2 immunopositive cell nuclei in corticotropinoma (woman, 29 years old, original magnification ×400). Fig. 5. Immunostaining
of intratumoral blood vessels walls with anti-D2 receptor antibody in gonadotropinoma (man,46 years old, original magnification ×400).
Fig. 6. D2 receptor immunostaining of endothelium in the intra-tumoral blood vessel. Gonadotropinoma (woman, 56 years old,  original
magnification ×400).
endothelial progenitor cells [18]. This findings was
confirmed by the observation of enhanced angiogene-
sis and malignant tumor growth in dopamine-depleted
or D2 receptor knockout mice [19]. The finding done
in the present study, that D2 receptor immunoreactivi-
ty are often detectable in vascular walls of pituitary
adenomas, suggests that D2-agonists may act, at least
in part, via suppression of tumoral angiogenesis. How-
ever, because we do not use the blockade of
immunoreaction with the excess of antigen protein, we
cannot totally exclude the unspecific  staining, partic-
ularly of the unusual localizations.
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